SG11201607133QA - Optimal dosing of a cd19-antibody drug conjugate - Google Patents

Optimal dosing of a cd19-antibody drug conjugate

Info

Publication number
SG11201607133QA
SG11201607133QA SG11201607133QA SG11201607133QA SG11201607133QA SG 11201607133Q A SG11201607133Q A SG 11201607133QA SG 11201607133Q A SG11201607133Q A SG 11201607133QA SG 11201607133Q A SG11201607133Q A SG 11201607133QA SG 11201607133Q A SG11201607133Q A SG 11201607133QA
Authority
SG
Singapore
Prior art keywords
drug conjugate
antibody drug
optimal dosing
dosing
optimal
Prior art date
Application number
SG11201607133QA
Other languages
English (en)
Inventor
Baiteng Zhao
Tina Albertson
Tae Han
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201607133QA publication Critical patent/SG11201607133QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
SG11201607133QA 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate SG11201607133QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461976790P 2014-04-08 2014-04-08
PCT/US2015/024732 WO2015157297A1 (en) 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate

Publications (1)

Publication Number Publication Date
SG11201607133QA true SG11201607133QA (en) 2016-09-29

Family

ID=54288332

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607133QA SG11201607133QA (en) 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate

Country Status (12)

Country Link
US (1) US20170182178A1 (es)
EP (1) EP3129052B1 (es)
JP (1) JP2017512801A (es)
KR (1) KR20160141727A (es)
CN (1) CN106170300A (es)
AU (1) AU2015244004A1 (es)
CA (1) CA2941154A1 (es)
EA (1) EA201692016A1 (es)
IL (1) IL247526A0 (es)
MX (1) MX2016012258A (es)
SG (1) SG11201607133QA (es)
WO (1) WO2015157297A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45625A (fr) * 2016-07-08 2019-05-15 Genmab As Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
CN109069584A (zh) * 2017-06-29 2018-12-21 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
EP3728330A4 (en) * 2017-12-23 2021-12-08 Uwell Biopharma Inc. PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG195524A1 (en) * 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
PT2211904T (pt) * 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
CN111012921A (zh) * 2010-06-15 2020-04-17 根马布股份公司 针对组织因子的人抗体药物缀合物
CA2815363C (en) * 2010-10-22 2020-07-14 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS

Also Published As

Publication number Publication date
CN106170300A (zh) 2016-11-30
EA201692016A1 (ru) 2017-01-30
EP3129052A1 (en) 2017-02-15
WO2015157297A1 (en) 2015-10-15
JP2017512801A (ja) 2017-05-25
EP3129052B1 (en) 2020-06-03
MX2016012258A (es) 2017-01-06
EP3129052A4 (en) 2017-11-15
US20170182178A1 (en) 2017-06-29
CA2941154A1 (en) 2015-10-15
AU2015244004A1 (en) 2016-09-15
IL247526A0 (en) 2016-11-30
KR20160141727A (ko) 2016-12-09

Similar Documents

Publication Publication Date Title
GB201402277D0 (en) Pharmaceutical compounds
GB201404922D0 (en) Pharmaceutical compounds
SG11201702298VA (en) Pharmaceutical preparation
GB201614443D0 (en) Targeted drug conjugates
PL3142740T3 (pl) Urządzenia do dostarczania leku
GB201416513D0 (en) Pharmaceutical compounds
IL247526A0 (en) Optimal dosage of cd19-antibody drug conjugate
PL2992967T3 (pl) Dozownik leku
GB201419540D0 (en) Delivery of drugs
HUE046373T2 (hu) Gyógyszercsomagolás
GB2528654B (en) Drug dispenser assembly
GB201406115D0 (en) New pharmaceutical use
GB201409662D0 (en) New pharmaceutical use
HRP20181406T1 (hr) Farmaceutski dozni oblici
GB201418984D0 (en) Novel drug conjugates
GB201503735D0 (en) A new drug application
GB201419996D0 (en) Targeted drug conjugates
AU358389S (en) Pharmaceutical capsule
GB201407533D0 (en) Targeted drug conjugates
GB201401818D0 (en) Targeted drug conjugates
GB201408176D0 (en) Ligand drug conjugates
GB201416627D0 (en) Pharmaceutical compounds
GB201416622D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds
GB201407741D0 (en) Novel drug formulation